Skip to main content

LianBio Issues Statement Regarding the HFCAA

Written by Customer Service on . Posted in Public Companies.

Company’s principal auditor is located in the United States and is currently inspected by the PCAOB

SHANGHAI and PRINCETON, N.J., March 10, 2022 (GLOBE NEWSWIRE) — Following the Determination Report of the Public Company Accounting Oversight Board (“PCAOB”) issued on December 16, 2021, on March 8, 2022 the U.S. Securities and Exchange Commission (the “SEC”) released a provisional list of companies identified as “Commission-Identified Issuers” under the Holding Foreign Companies Accountable Act (“HFCAA”). LianBio (Nasdaq: LIAN) is not currently on this list and does not expect to be named by the SEC as a “Commission Identified Issuer” under the HFCAA.

Unlike the companies currently identified on the SEC’s provision list, LianBio’s retained principal auditor is a large independent public accounting firm located in New York, USA and is currently inspected by the PCAOB. Therefore, LianBio does not believe it will be subject to the provisions under the HFCAA that are applicable to issuers whose auditors are located in a foreign jurisdiction and that the PCAOB is unable to inspect or investigate.

Important information and disclosures on these topics contained in LianBio’s public filings are available on its website and at www.sec.gov.

About LianBio
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit www.lianbio.com

For media inquiries, please contact:
katherine.smith@canalecomm.com

For investor inquiries, please contact:
IR@lianbio.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.